Navigation Links
Optimer Pharmaceuticals Provides Update on DIFICID® (fidaxomicin) Tablets Launch
Date:1/9/2012

ptimer's ability to continue driving adoption and use of DIFICID, whether healthcare professionals will prescribe DIFICID, whether DIFICID will receive or continue to receive reimbursement coverage from healthcare payers and government agencies, the extent to which DIFICID will be accepted on hospital formularies and potential delays in formulary decisions, Optimer's ability to successfully coordinate commercialization efforts with Cubist Pharmaceuticals under its co-promotion agreement, whether Optimer will be able to realize expected benefits under its co-promotion agreement with Cubist, the fact that past results may not be predictive of future results of performance, the possibility of alternative means of preventing or treating DIFICID impacting adoption and sales of DIFICID, Optimer's ability, though its third party manufacturers and logistics providers, to maintain a sufficient supply of DIFICID to meet demand, Optimer's ability to pursue new indications for DIFICID, whether any studies intended to support additional indications for DIFICID will be successful, whether any new indications for DIFICID will be approved by the FDA and other risks detailed in Optimer's filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this release, and Optimer undertakes no obligation to update or revise these statements, except as may be required by law.

Contacts
Optimer Pharmaceuticals, Inc.
David Walsey, Vice President, Investor Relations and Corporate Communications
(858) 909-0736

Canale Communications, Inc.
Jason I. Spark, Senior Vice President
(619) 849-6005

 


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Optimer Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
2. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3. Optimer Pharmaceuticals to Present at BioCentury Newsmakers Conference
4. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
5. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
6. Optimer Pharmaceuticals DIFICID Featured in 11 Presentations at 51st ICAAC
7. Optimer Pharmaceuticals to Present at September 2011 Investor Conferences
8. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
9. Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimers DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin
10. Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results
11. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sciences, Inc. (NASDAQ: ALIM ) (Alimera), a ... commercialization of prescription ophthalmic pharmaceuticals, announced today that it ... Growth Capital, Inc. (NYSE: HTGC ) (Hercules). ... the Loan and Security Agreement that Alimera,s subsidiary in ... Limited, entered into with Hercules in April of this ...
(Date:9/30/2014)... , Sept. 30, 2014 A study using ... offered a new look at the composition of carotid ... physicians understand and treat the disease, a leading cause ... Baptist Health Lexington between September 2010 and May 2012, ... Journal of the American College of Cardiology (JACC) ...
(Date:9/30/2014)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... Bridgewater, New Jersey location received ... Administration (FDA) relating to an inspection in June 2014 ... injectable, which was divested to Galderma S.A. in July ... contract manufacturers (rather than Valeant,s own internal manufacturing) with ...
Breaking Medicine Technology:Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2
... DIEGO, June 7, 2011 Tocagen Inc. ... high grade glioma, such as those with glioblastoma multiforme ... Toca 511. The multicenter, open-label study is ... of Toca 511 administered intratumorally followed by cycles of ...
... 2011 Topaz Pharmaceuticals Inc., a privately held specialty ... Drug Administration (FDA) accepted for filing the New Drug ... as a treatment for head lice infestations in children ... transition of the Company from the development phase as ...
Cached Medicine Technology:Tocagen's First-in-Human Clinical Trial of Toca 511 Enrolling Patients with High Grade Glioma 2Topaz Pharmaceuticals Announces New Drug Application for the Treatment of Head Lice Accepted by FDA 2Topaz Pharmaceuticals Announces New Drug Application for the Treatment of Head Lice Accepted by FDA 3
(Date:9/30/2014)... (PRWEB) September 30, 2014 Integrated ... wellness, is opening another new medical specialty practice through ... IMA Cardiology will be located within the company’s ... Abbud and Dr. Isaac Tawfik of American Heart Center, ... The new practice will offer Integrated Medicine Alliance patients ...
(Date:9/30/2014)... has been awarded a three-year $1.7 million grant ... develop new imaging technologies and data analysis techniques ... networks of neurons in the brain interact to ... identify the precise interactions between millions of nerve ... and alterations in these interactions that may be ...
(Date:9/30/2014)... Elevate , the latest product from Blue Start ... of the gym by providing natural ingredients that boost brain ... Michaels, prompting an investigative review. , “When it comes ... simply just don’t have the ability to perform the way ... the motivation to finish a project, or even feeling like ...
(Date:9/30/2014)... 30, 2014 Hospice & Palliative ... “In Celebration” gala, honoring three outstanding individuals for ... striving to provide extraordinary and dignified comfort, care ... serious or life-limiting illness. , The event was ... NY and recognized William (Bill) J. McGuinness, Director ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Dr. Karl ... knee pain program of care that is dramatically ... , His clinic—Johnson Chiropractic Neurology & Nutrition—applies a proprietary, ... knee. It also addresses sources of inflammation, neurology of ... the “neurokinetic chain” from the brain to the spine, ...
Breaking Medicine News(10 mins):Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 3
... computer tomography (CT) scans, imaging plays an important ... high-quality images often requires advanced technology and expertise, ... launches its preparatory phase today, aims to provide ... imaging technologies at all levels of biological and ...
... News) -- A problem in the lining of blood vessels ... according to a new study. The condition, called endothelial ... the layer of cells that line blood vessels. Nitric oxide ... improves blood flow and the delivery of oxygen and nutrients ...
... today at the annual meeting of the Radiological Society ... ionizing radiation from imaging procedures and efforts under way ... on the risks and benefits of medical imaging. ... chairman of the Department of Diagnostic Radiology at Yale ...
... , WEDNESDAY, Dec. 1 (HealthDay News) -- ... new study contends. The study included nearly 600 ... disorder that causes severe pain and diarrhea. The ... the study and 19 percent of them were found ...
... A U.S. Food and Drug Administration advisory committee on Wednesday ... prostate cancer, the third-highest cancer killer of men. ... of Merck,s Proscar outweighed its benefits, according to the ... voted 14-2, with two abstentions, against GlaxoSmithKline,s Avodart. Both drugs ...
... Ore. Young women veterans are nearly three times ... new research published by researchers at Portland State University ... The paper, "Self-Inflicted Deaths Among Women With U.S. ... 2010 issue of Psychiatric Services , a journal ...
Cached Medicine News:Health News:Better imaging from bench to bedside 2Health News:New Piece of Alzheimer's Puzzle Identified 2Health News:Expert panel addresses safety in medical imaging 2Health News:Expert panel addresses safety in medical imaging 3Health News:Study Suggests Link Between Crohn's Disease and PTSD 2Health News:FDA Panel Votes Against Drugs Said to Prevent Prostate Cancer 2Health News:Suicide rate among young women veterans more than twice that of civilians 2
Tying forceps with 6.5 mm tying platform. Round handle with flats provide flexibility of round handle with the stability of a flat handle. Curved shafts. Overall length 3.9 inches....
Delicate curved tying forcep with round handle is excellent for all fine suturing techniques. Useful for corneal transplants where delicate control is required....
Straight, 7 mm tying platform. Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Straight 6 mm platform. McPherson handle. Manufactured in titanium. Overall length 3.3 inches....
Medicine Products: